Genentech Inc. DNA
Genentech, Inc. engages in the discovery, development, manufacture, and commercialization of biotherapeutics in the United States.
DNA has grown earnings at an annual rate of almost 50% the last 5 years. Even if one is to estimate a modest growth rate of 25% over the next 5 years, DNA is still very cheap on a valuation basis. The stock price has not been this low since May of 2005 and is currently trading more than 20% below is 52 week high set in January. DNA is expected to earn between $3.20 to $3.80 next year meaning its trading at 20-22 times next years earnings. I am a buyer at this price. I am looking for $100 + over the next 12 months.
Saturday, August 11, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment